Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib and Lutetium 177 Dotatate in GEP-NETs
NCT04750954Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of peposertib in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase 2 Dose at 8 weeks and Dose Limiting Toxicity at 24 months. Started Jul 2021; status: active, not recruiting.
02
Drugs
peposertib
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04750954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750954.